Verastem Inc (FRA:2VSA)
€ 4.06 0.24 (6.28%) Market Cap: 193.89 Mil Enterprise Value: 145.66 Mil PE Ratio: 0 PB Ratio: 16.62 GF Score: 35/100

Verastem Inc at JMP Securities Life Sciences Conference Transcript

May 16, 2023 / 05:00PM GMT
Release Date Price: €3.83 (+4.59%)
Reni Benjamin
JMP Securities LLC - Analyst

We'll go ahead and get started. Good afternoon, everyone. Welcome to the second day of the JMP Securities Life Sciences Conference.

Our next presenting company is Verastem Oncology. Verastem is developing several molecules. One, which targeting the RAS pathway. The other one, the FAK inhibitor, which I remember from way back when. Here to tell us about the company is Dan Paterson, President and Chief Operating Officer.

Dan Peterson
Verastem, Inc. - President & COO

Thanks, Ren. It's a good to actually get out between the pandemic and execution. Haven't been out in quite a while and commute in New York for the first time in three years. I noticed ties are missing and there's no cabs anywhere. So it's a little different.

Anyway, very exciting time for Verastem. I'm glad to tell you an update on the story. Safe Harbor. I will be talking about forward-looking statements.

So it is a really exciting time for us. We're really well positioned for what we're hoping will be an uptick in the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot